Chemical Structure (Duloxetine 01)
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-9187
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-9187). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Duloxetine 02)
Figure 2 (Duloxetine 03)
The figure shows the proportion of patients with relapse over time in days from randomization in a clinical trial comparing a placebo to duloxetine delayed-release capsules. As time passes, a higher proportion of patients in the placebo group relapse compared to those in the duloxetine group.*
Figure 3 (Duloxetine 04)
Figure 4 (Duloxetine 05)
Figure 5 (Duloxetine 06)
The text seems to be a chart that shows the percentage of improvement in pain from baseline among patients who received either DUL 50mg once daily, DUL 50mg twice daily, or a placebo. It does not provide specific numerical values for the percentage of improvement.*
Figure 6 (Duloxetine 07)
Figure 8 (Duloxetine 08)
The text displays a chart comparing the percentage of patients with improved pain levels in a placebo group versus a group treated with DUL 60/120 mg once daily. The chart shows that 80% of patients treated with DUL showed improvement compared to 70% of the placebo group. The x-axis displays percentage levels of improvement from 0% to 100%.*
Figure 9 (Duloxetine 09)
This text shows a chart displaying the percentage of patients who improved their pain levels after taking either a placebo or DUL 60 mg once daily. The chart also represents the percent improvement in pain from baseline in a BOCF analysis.*
Figure 10 (Duloxetine 10)
The graph shows the percentage of patients improved in terms of pain management. The x-axis represents the percent improvement in pain from baseline, and the y-axis displays the different treatments. The placebo treatment displayed no improvement in pain management, while the faga - DULB0/120 mg once daily treatment had a 100% improvement in pain management. The numbers on the x-axis range from 0 to 290.*
Label (Lbl636299187)
This is a prescription medication named Duloxetine Hydrochloride USP, containing 40 mg Duloxetine per capsule. The package contains 30 capsules that should be stored at 25°C and away from children. It is recommended to read the accompanying literature for dosage information and the medication guide should be dispensed to each patient. The NDC number is 63629-9187-01.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
